UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 518

Sortiert nach

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

The Lancet (British edition), 2009-06, Vol.373 (9681), p.2125-2135

2009

Volltextzugriff (PDF)

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

The New England journal of medicine, 2006-12, Vol.355 (23), p.2427-2443

2006

Volltextzugriff (PDF)

Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes

Diabetes (New York, N.Y.), 2006-08, Vol.55 (8), p.2357-2364

2006

Volltextzugriff (PDF)

Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial

American journal of nephrology, 2021-03, Vol.52 (1), p.26-35

2021

Volltextzugriff (PDF)

Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis

The New England journal of medicine, 2007-07, Vol.357 (1), p.28-38

2007

Volltextzugriff (PDF)

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics

The American heart journal, 2018-09, Vol.203, p.30-38

2018

Volltextzugriff (PDF)

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

European heart journal, 2010-04, Vol.31 (7), p.824-831

2010

Volltextzugriff (PDF)

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2010-01, Vol.95 (1), p.134-142

2010

Volltextzugriff (PDF)

Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome

Arteriosclerosis, thrombosis, and vascular biology, 2012-09, Vol.32 (9), p.2289

2012

Volltextzugriff (PDF)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)

Cardiovascular diabetology, 2008-04, Vol.7 (1), p.10-10

2008

Volltextzugriff (PDF)

Cancer and bone fractures in observational follow-up of the RECORD study

Acta diabetologica, 2015-06, Vol.52 (3), p.539-546

2015

Volltextzugriff (PDF)

A Diabetes Outcome Progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

Diabetes care, 2002-10, Vol.25 (10), p.1737-1743

2002

Volltextzugriff (PDF)

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes

Nutrition, metabolism, and cardiovascular diseases, 2007-01, Vol.17 (1), p.13-23

2007

Volltextzugriff (PDF)

Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study

Diabetes care, 2011-06, Vol.34 (6), p.1394-1396

2011

Volltextzugriff (PDF)

A Diabetes Outcome Progression Trial (ADOPT)

Diabetes care, 2002-10, Vol.25 (10), p.1737-1743

2002

Volltextzugriff (PDF)

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

The Lancet (British edition), 2018-10, Vol.392 (10157), p.1519-1529

2018

Volltextzugriff (PDF)

Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients

Obesity (Silver Spring, Md.), 2002-10, Vol.10 (10), p.1008-1015

2002

Volltextzugriff (PDF)

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis

Clinical therapeutics, 2003-11, Vol.25 (11), p.2754-2764

2003

Volltextzugriff (PDF)

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

Diabetes, obesity & metabolism, 2003-05, Vol.5 (3), p.163-170

2003

Volltextzugriff (PDF)

Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes

Diabetes care, 2011-06, Vol.34 (6), p.1394-1396

2011

Volltextzugriff (PDF)

Heart failure events with rosigtitazone in type 2 diabetes: data from the RECORD clinical trial

European heart journal, 2010, Vol.31 (7), p.824-831

2010

Volltextzugriff (PDF)

Rosiglitazone evaluated for cardio-vascular outcomes - An interim analysis

The New England journal of medicine, 2007-07, Vol.357 (1), p.28

2007

Volltextzugriff (PDF)

Rosiglitazone Treatment Does Not Impair the Triglyceride-Lowering Activity of Fibrates in Patients with Type 2 Diabetes Mellitus

Diabetes (New York, N.Y.), 2000-05, Vol.49 (5), p.A359

2000

Volltextzugriff (PDF)

Rosiglitazone Treatment Reduces Gamma-Glutamyltransferase Levels, a Marker for Visceral and Hepatic Fat

Diabetes (New York, N.Y.), 2000-05, Vol.49 (5), p.A120

2000

Volltextzugriff (PDF)

Rosiglitazone added to a sulphonylurea: Effective and well tolerated in patients with type 2 diabetes and mild to moderate renal impairment

Diabetes research and clinical practice, 2000-09, Vol.50, p.257-257

2000

Volltextzugriff (PDF)

1 – 25 von 518

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(479)
Mit Volltextzugriff
(442)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(388)
Life Sciences & Biomedicine
(320)
Humans
(273)
Male
(136)
Female
(128)
Biological And Medical Sciences
(111)
Middle Aged
(83)
Animals
(81)
Medical Sciences
(77)
Adult
(71)
Aged
(66)
Neurosciences & Neurology
(53)
General & Internal Medicine
(46)
Mutation
(45)
Science & Technology - Other Topics
(43)
Fundamental And Applied Biological Sciences. Psychology
(42)
Multidisciplinary Sciences
(41)
Genomes
(40)
Medicin Och Hälsovetenskap
(38)
Clinical Neurology
(37)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes

Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial

Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes

Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)

Cancer and bone fractures in observational follow-up of the RECORD study

A Diabetes Outcome Progression trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes

Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study

A Diabetes Outcome Progression Trial (ADOPT)

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Effect of Rosiglitazone on Insulin Sensitivity and Body Composition in Type 2 Diabetic Patients

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis

Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes

Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes

Heart failure events with rosigtitazone in type 2 diabetes: data from the RECORD clinical trial

Rosiglitazone evaluated for cardio-vascular outcomes - An interim analysis

Rosiglitazone Treatment Does Not Impair the Triglyceride-Lowering Activity of Fibrates in Patients with Type 2 Diabetes Mellitus

Rosiglitazone Treatment Reduces Gamma-Glutamyltransferase Levels, a Marker for Visceral and Hepatic Fat

Rosiglitazone added to a sulphonylurea: Effective and well tolerated in patients with type 2 diabetes and mild to moderate renal impairment

Suchergebnisse filtern